Editas Medicine Linkedin .hamburger .st0{fill:none;stroke:#FFFFFF;stroke-width:0.5;} Overview Press Releases Posters & Presentations Media Contact EDITAS MEDICINE’S NEWSROOM Editas Medicine is a leading gene editing company dedicated to developing gene edited medicines for people living with serious diseases around the world. Check out our press releases and other company information to stay apprised of the latest news. Press Releases Recent Any 2019 2018 2017 2016 2015 2014 2013 2012 November 12, 2021 Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting November 8, 2021 Editas Medicine Announces Third Quarter 2021 Results and Business Updates November 4, 2021 Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition October 28, 2021 Editas Medicine Names Bernadette Connaughton to Board of Directors October 25, 2021 Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update October 20, 2021 Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress See all Posters and Presentations We ground our work in a wide range of fundamental scientific knowledge. 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 November 12, 2021 Alexander G. Allen, et al. GAPDH knock-in of high-affinity CD16 and mbIL-15 in iPSC-derived NK cells drives high-level expression and increased anti-tumor function. Presented at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, November 10-14, 2021. Download September 23, 2021 John Zuris. An Engineered AsCas12a Nuclease Facilitates the Rapid Generation of Therapeutic Cell Medicines. Presented at TIDES USA Oligonucleotide and Peptide Therapeutics, September 20-23, 2021. Download September 23, 2021 Keith Jarvis. IND-enabling Small-Scale Guide RNA Production Under GMP for CRISPR Based Cell Therapies. Presented at TIDES USA Oligonucleotide and Peptide Therapeutics, September 20-23, 2021. Download September 23, 2021 Steve Wolk. Characterization of gRNAs and Ribonucleoproteins for CRISPR Applications. Presented at TIDES USA Oligonucleotide and Peptide Therapeutics, September 20-23, 2021. Download September 21, 2021 Jean-Noel Lemercier, et al. Characterization of CRISPR RNPs by Ion-Exchange Chromatography. Presented at TIDES USA Oligonucleotide and Peptide Therapeutics, September 20-23, 2021. Download September 21, 2021 Pranjali Ghude, et al. Understanding CRISPR RNA Secondary Structure Impact on Ribonucleoprotein (RNP) Behavior by SEC-PAGE. Presented at TIDES USA Oligonucleotide and Peptide Therapeutics, September 20-23, 2021. Download August 20, 2021 J. A. Zuris. A Method for Highly Efficient Knock-in and Expression of Transgene Cargos for Next Generation Cell-based Medicine. Presented at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers meeting, August 18-20, 2021. Download August 18, 2021 Eugenio Marco et al. CALITAS: a CRISPR-Cas-aware ALigner for In silico off-TArget Search. Presented at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers meeting, August 18-20, 2021. Download June 11, 2021 Edouard De Dreuzy, et al. Preclinical Data Supporting the Initiation of the EDIT-301 Phase I/II RUBY Clinical Trial for the Potential Treatment of Sickle Cell Disease. Presented at the 26th Congress of the European Hematology Association (EHA), June 9 – 17, 2021. Download May 11, 2021 M. Allocca, D. Reyon, et al. Advances Toward a Dual AAV CRISPR-Cas9-based “Knockout and Replace” Strategy to Treat Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa. The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 11 – 14, 2021 Download May 10, 2021 H. MacLeod. The development of CRISPR-based medicines for the treatment of ocular diseases. The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 11 – 14, 2021 Download May 4, 2021 N. Dilmac, et al. CRISPR Gene Editing Rescues Deficits in Human USH2A Mutant Retinal Organoids. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 1-7, 2021 Download May 3, 2021 M. Allocca, et al. Advances Toward a Dual AAV CRISPR-Cas9-based “Knockout and Replace” Strategy to Treat Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 1-7, 2021 Download April 10, 2021 K. Wong, et al. CRISPR-Cas12a Gene Editing Enhances Functional Metabolism of Natural Killer Cells and Enables Tumor Cell Cytolysis in Metabolically Stressful Conditions That Inhibit Effector Cell Function. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 10 – 15, 2021 Download April 10, 2021 Christopher M. Borges, et al. A Multiplexed CRISPR-Cas12a Gene-Edited Healthy Donor-Derived NK Cell Therapy with Increased Granzyme B and Degranulation Supports Improved Serial Killing Capacity. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 10 – 15, 2021 Download Media Contact Cristi Barnett cristi.barnett@editasmed.com 617.401.0113 Research and Pipeline CRISPR Gene Editing For Patients Who We Are Join Our Team Investors Terms of Use Privacy Policy Get in Touch Newsroom Editas Medicine Linkedin ©Copyright 2021 Editas Medicine